The U.S. Court of Appeals for the Federal Circuit has reinstated its ruling that a company’s isolation of human genetic material, and its process for using that material to determine the effectiveness of certain cancer therapies, meet the threshold test for patent-eligibility.
McCarter & English attorney Maria Zacharakis was quoted in a Rhode Island and Massachusetts Lawyers Weekly article entitled “Federal Circuit ruling another win for biotech industry.”